

S33: Prolyl aminopeptidase in GtoPdb v.2025.3

Stephen P.H. Alexander¹, Patrick Doherty² and Christopher J. Fowler³

1. University of Nottingham, UK
2. King's College London, UK
3. University Hospital of Umeå, Sweden

Abstract

Peptidase family S33 contains mainly exopeptidases that act at the N-terminus of peptides.

Contents

This is a citation summary for S33: Prolyl aminopeptidase in the [Guide to Pharmacology](#) database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

[GtoPdb](#) is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [\[4\]](#).

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

[S33: Prolyl aminopeptidase](#)

<https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=917>

Enzymes

[lipase, gastric](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2626>

[protein phosphatase methylesterase 1](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2875>

[MAGL\(monoacylglycerol lipase\)](#)

<https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399>

References

1. Aaltonen N, Savinainen JR, Ribas CR, Rönkkö J, Kuusisto A, Korhonen J, Navia-Paldanius D, Häyrynen J, Takabe P and Käsänen H *et al.* (2013) Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. *Chem Biol* **20**: 379-90 [PMID:23521796]
2. Bachovchin DA, Koblan LW, Wu W, Liu Y, Li Y, Zhao P, Woznica I, Shu Y, Lai JH and Poplawski SE *et al.* (2014) A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. *Nat Chem Biol* **10**: 656-63 [PMID:24997602]
3. Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, Brown SJ, Rosen H and Cravatt BF. (2011) Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. *J Med Chem* **54**: 5229-36 [PMID:21639134]
4. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020**

[PMID:32367113]

5. Chang JW, Niphakis MJ, Lum KM, Cognetta 3rd AB, Wang C, Matthews ML, Niessen S, Buczynski MW, Parsons LH and Cravatt BF. (2012) Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. *Chem Biol* **19**: 579-88 [PMID:22542104]
6. Cisar JS, Weber OD, Clapper JR, Blankman JL, Henry CL, Simon GM, Alexander JP, Jones TK, Ezekowitz RAB and O'Neill GP *et al.* (2018) Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. *J Med Chem* **61**: 9062-9084 [PMID:30067909]
7. Clapper JR, Henry CL, Niphakis MJ, Knize AM, Coppola AR, Simon GM, Ngo N, Herbst RA, Herbst DM and Reed AW *et al.* (2018) Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators. *J Pharmacol Exp Ther* **367**: 494-508 [PMID:30305428]
8. Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR and Fowler CJ. (2004) Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. *Br J Pharmacol* **143**: 774-84 [PMID:15492019]
9. Granchi C, Rizzolio F, Bordon V, Caligiuri I, Manera C, Macchia M, Minutolo F, Martinelli A, Giordano A and Tuccinardi T. (2016) 4-Arylidene-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors. *J Enzyme Inhib Med Chem* **31**: 137-46 [PMID:25669350]
10. Ikeda S, Sugiyama H, Tokuhara H, Murakami M, Nakamura M, Oguro Y, Aida J, Morishita N, Sogabe S and Dougan DR *et al.* (2021) Design and Synthesis of Novel Spiro Derivatives as Potent and Reversible Monoacylglycerol Lipase (MAGL) Inhibitors: Bioisosteric Transformation from 3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl Moiety. *J Med Chem* **64**: 11014-11044 [PMID:34328319]
11. Jiang M, Huizenga MCW, Wirt JL, Paloczi J, Amedi A, van den Berg RJBHN, Benz J, Collin L, Deng H and Di X *et al.* (2023) A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. *Nat Commun* **14**: 8039 [PMID:38052772]
12. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE and Parsons LH *et al.* (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol* **5**: 37-44 [PMID:19029917]
13. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH and Wiley JL *et al.* (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proc Natl Acad Sci USA* **106**: 20270-5 [PMID:19918051]
14. Niphakis MJ, Cognetta 3rd AB, Chang JW, Buczynski MW, Parsons LH, Byrne F, Burston JJ, Chapman V and Cravatt BF. (2013) Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors. *ACS Chem Neurosci* **4**: 1322-32 [PMID:23731016]
15. Niphakis MJ, Johnson DS, Ballard TE, Stiff C and Cravatt BF. (2012) O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors. *ACS Chem Neurosci* **3**: 418-26 [PMID:22860211]
16. Petersen A, Benz J, Grether U, Hornsperger B, Kocer B, Kuhn B, Richter H, Tsuchiya S, Qui Y and Chen R. (2019) Octahydropyrido[1,2- α]pyrazines as magl inhibitors Patent number: WO2019134985A1. Assignee: Hoffmann-La Roche. Priority date: 08/01/2018. Publication date: 11/07/2019.
17. Wyatt RM, Fraser I, Welty N, Lord B, Wennerholm M, Sutton S, Ameriks MK, Dugovic C, Yun S and White A *et al.* (2020) Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor. *J Pharmacol Exp Ther* **372**: 339-353 [PMID:31818916]
18. Xiong F, Ding X, Zhang H, Luo X, Chen K, Jiang H, Luo C and Xu H. (2021) Discovery of novel reversible monoacylglycerol lipase inhibitors via docking-based virtual screening. *Bioorg Med Chem Lett* **41**: 127986 [PMID:33766770]
19. Zhi Z, Zhang W, Yao J, Shang Y, Hao Q, Liu Z, Ren Y, Li J, Zhang G and Wang J. (2020) Discovery of Aryl Formyl Piperidine Derivatives as Potent, Reversible, and Selective Monoacylglycerol Lipase Inhibitors. *J Med Chem* **63**: 5783-5796 [PMID:32429662]